Balchem Corporation is a specialty chemicals business based in the US. Balchem Corporation shares (BCPC) are listed on the NASDAQ and all prices are listed in US Dollars. Its last market close was $178.03 – an increase of 0.68% over the previous week. Balchem Corporation employs 1,300 staff and has a trailing 12-month revenue of around $942.4 million.
Paid non-client promotion. Finder does not invest money with providers on this page. If a brand is a referral partner, we're paid when you click or tap through to, open an account with or provide your contact information to the provider. Partnerships are not a recommendation for you to invest with any one company. Learn more about how we make money.
Finder is not an advisor or brokerage service. Information on this page is for educational purposes only and not a recommendation to invest with any one company, trade specific stocks or fund specific investments. All editorial opinions are our own.
| Latest market close | $178.03 |
|---|---|
| 52-week range | $119.79 - $186.03 |
| 50-day moving average | $172.53 |
| 200-day moving average | $160.81 |
| Wall St. target price | $190.33 |
| PE ratio | 47.6604 |
| Dividend yield | $0.79 (0.44%) |
| Earnings per share (TTM) | $3.71 |
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
Historical closes compared with the close of $177.53 from 2024-11-19
| 1 week (2024-11-14) | 0.40% |
|---|---|
| 1 month (2024-10-21) | 5.81% |
| 3 months (2024-08-21) | 4.88% |
| 6 months (2024-05-21) | 14.17% |
| 1 year (2023-11-21) | 45.27% |
|---|---|
| 2 years (2022-11-21) | 26.50% |
| 3 years (2021-11-19) | 7.94% |
| 5 years (2019-11-21) | 84.54% |
Valuing Balchem Corporation stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of Balchem Corporation's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.
Balchem Corporation's current share price divided by its per-share earnings (EPS) over a 12-month period gives a "trailing price/earnings ratio" of roughly 48x. In other words, Balchem Corporation shares trade at around 48x recent earnings.
That's relatively high compared to, say, the trailing 12-month P/E ratio for the NASDAQ 100 at the end of 2019 (27.29). The high P/E ratio could mean that investors are optimistic about the outlook for the shares or simply that they're over-valued.
Balchem Corporation's "price/earnings-to-growth ratio" can be calculated by dividing its P/E ratio by its growth – to give 4.7739. A low ratio can be interpreted as meaning the shares offer better value, while a higher ratio can be interpreted as meaning the shares offer worse value.
The PEG ratio provides a broader view than just the P/E ratio, as it gives more insight into Balchem Corporation's future profitability. By accounting for growth, it could also help you if you're comparing the share prices of multiple high-growth companies.
Balchem Corporation's EBITDA (earnings before interest, taxes, depreciation and amortisation) is $215.1 million.
The EBITDA is a measure of a Balchem Corporation's overall financial performance and is widely used to measure a its profitability.
| Revenue TTM | $942.4 million |
|---|---|
| Operating margin TTM | 20.22% |
| Gross profit TTM | $280.5 million |
| Return on assets TTM | 6.42% |
| Return on equity TTM | 11.04% |
| Profit margin | 12.9% |
| Book value | $36.21 |
| Market Capitalization | $5.7 billion |
TTM: trailing 12 months
Dividend payout ratio: 28.3% of net profits
Recently Balchem Corporation has paid out, on average, around 0% of net profits as dividends. That has enabled analysts to estimate a "forward annual dividend yield" of 0% of the current stock value. This means that over a year, based on recent payouts (which are sadly no guarantee of future payouts), Balchem Corporation shareholders could enjoy a 0% return on their shares, in the form of dividend payments. In Balchem Corporation's case, that would currently equate to about $0.79 per share.
While Balchem Corporation's payout ratio might seem fairly standard, it's worth remembering that Balchem Corporation may be investing much of the rest of its net profits in future growth.
Balchem Corporation's most recent dividend payout was on 18 January 2024. The latest dividend was paid out to all shareholders who bought their shares by 25 December 2023 (the "ex-dividend date").
Balchem Corporation's shares were split on a 3:2 basis on 20 January 2010 . So if you had owned 2 shares the day before before the split, the next day you'd have owned 3 shares. This wouldn't directly have changed the overall worth of your Balchem Corporation shares – just the quantity. However, indirectly, the new 33.3% lower share price could have impacted the market appetite for Balchem Corporation shares which in turn could have impacted Balchem Corporation's share price.
Over the last 12 months, Balchem Corporation's shares have ranged in value from as little as $119.7905 up to $186.03. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Balchem Corporation's is 0.651. This would suggest that Balchem Corporation's shares are less volatile than average (for this exchange).
Balchem Corporation develops, manufactures, and markets specialty performance ingredients and products for the nutritional, food, pharmaceutical, animal health, medical device sterilization, plant nutrition, and industrial markets worldwide. It operates through three segments: Human Nutrition and Health, Animal Nutrition and Health, and Specialty Products. The Human Nutrition & Health segment supplies ingredients in the food and beverage industry. Its products include spray dried and emulsified powders, extrusion and agglomeration, blended lipid systems, liquid flavor delivery systems, juice and dairy bases, chocolate systems, and cereal systems, as well as ice cream bases and variegates. This segment also offers specialty vitamin K2; microencapsulation solutions for various applications; and human grade choline nutrients and mineral amino acid chelated products for nutrition and health applications. The Animal Nutrition & Health segment provides microencapsulated products to enhance health and milk production, and delivering nutrient supplements in ruminant animals; chelation technology, which offers enhanced nutrient absorption for various species of production and companion animals; methylsulfonylmethane; and choline chloride, a nutrient for monogastric animal health. The Specialty Products segment distributes ethylene oxide and ammonia primarily for use in the health care industry; and single use canisters for sterilizing re-usable devices.
Robinhood Launches Presidential Election Event Contracts Ahead of the Nov 5 Presidential Election
Explore the best bonuses for opening a new brokerage account.
These are the best trading platforms for beginners, according to Finder’s comprehensive analysis.
Compare pros, cons, research tools and reviews for these two trading platforms.
Check out our picks of the best trading apps for beginners, options traders, hands-off investors and more.
See our picks of the best brokerage accounts, including Fidelity, SoFi, Charles Schwab, Public, Robinhood and E*TRADE .
What you need to know about investing in the leading indicator for the overall US stock market.
Maximize $10,000 with broker bonuses, IRA contribution matches, index funds, stocks, ladder CDs, hiring a financial advisor and more.
Top ways to invest $20K include stocks, retirement accounts, conservative investments, ETFs and more. See our full list here.
A deep dive into the highlights and limitations of Robinhood.